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Abstract 
Background: Panic disorder is a mental disorder of high prevalence, which frequently co‑occurs with agorapho‑
bia. There is a lack of studies measuring excess costs of panic disorder patients with and without agoraphobia. We 
compared costs of panic disorder patients with or without agoraphobia with costs of the anxiety‑free population in 
Germany.
Methods: Primary data from a cluster‑randomized trial of adults suffering from panic disorder (n = 419) and from a 
representative survey of the German general population (N = 5005) were collected between 2012 and 2014. Missing 
data from the cluster‑randomized trial were first imputed by multiple imputation using chained equations and sub‑
sequently balanced with the data from the survey by Entropy Balancing. The societal perspective was chosen. Excess 
costs were calculated by generalized linear models and two‑part‑models.
Results: Entropy Balancing led to an exact match between the groups. We found 6‑month total excess costs of 
3220€ (95% CI 1917€–4522€) for panic disorder patients without agoraphobia and of 3943€ (95% CI 2950€–4936€) for 
patient with agoraphobia. Panic disorder patients with or without agoraphobia had significantly higher costs for psy‑
chotherapy, general practitioners, general hospital stays and informal care Indirect costs accounted for approximately 
60% of the total excess costs.
Conclusions: Panic disorder with or without agoraphobia is associated with significant excess costs. Agoraphobia 
changes the pattern of resource utilization. Especially indirect costs are relevant. Agoraphobia influences resource 
utilization in the inpatient sector.
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Introduction
Panic disorder, defined as recurrent, unpredictable panic 
attacks associated with feelings of unreality, chest pain, 
palpitations, choking sensations, and dizziness [1], poses 
a major challenge to the health care system. According 
to the representative DEGS1-MH study, in Germany the 
12-month prevalence of panic disorder (with or without 
agoraphobia) is approximately 2.0% in the general adult 
population, with women being affected twice as often 
as men (prevalence rate of 2.8% vs. 1.2%) [2]. This study 
considered the German adult population aged 18 to 79. 
Based on data of the German Statistical Office, this age 
group consisted of around 64 million people in 2016 [3]. 
This means that around 1.28 million people in Germany 
suffered from panic disorder (with or without agorapho-
bia). Comorbidity among anxiety disorders is very com-
mon, with the highest rates found in panic disorder [4]. 
Agoraphobia is a frequent comorbidity in panic disorder 
patients. There is evidence that approximately 35% to 
65% of the panic disorder patients are affected by agora-
phobia [5].
The evidence highlights the challenge posed by fre-
quency. Further evidence underlines the challenge posed 
by health burden. A study by Saarni et  al. [6] showed 
that health-related quality of life was decreased for panic 
disorder patients as well as for patients with agorapho-
bia compared to individuals without a mental disorder 
[based on a composite international diagnostic interview 
(CIDI)]. Additionally, Beard et al. [7] reported that panic 
disorder patients with agoraphobia had lower physical 
and mental component scores in the Short-Form 36 com-
pared to panic disorder patients without agoraphobia. 
Both studies indicate that the health burden of panic dis-
order with and without agoraphobia is high.
In addition, several studies emphasized the challenges 
to health care delivery and financing. Prospective lon-
gitudinal studies have shown that misinterpretation of 
bodily sensations and health anxiety are important fac-
tors which might contribute to elevated help-seeking in 
the health care system [8, 9]. Furthermore, the economic 
burden of panic disorder has been addressed by several 
international studies [10]. However, only one study from 
the Netherlands analysed the economic burden of panic 
disorder with a special view on agoraphobia [11]. The 
authors of this study differentiated between full-blown 
and subthreshold panic disorder with or without agora-
phobia. They found that in case of a panic disorder ago-
raphobia raises the annual costs from around €12,000 to 
€15,000, while in case of subthreshold panic disorder the 
increase is even more pronounced, from around €6700 
to nearly €17,000. Based on these results, we expect that 
in our study patients with a comorbid agoraphobia will 
have higher costs, too. However, due to methodological 
differences, we abstain from deriving assumptions about 
the amount of the difference and will not be able to com-
pare the findings of Batelaan et al. to our results.
The special need to address these challenges has 
been recognized by German researchers and disease-
specific interventions have been developed, imple-
mented and assessed, e.g. the Jena-Paradise study 
(ISRCTN64669297). However, there is no scientific evi-
dence regarding the impact of panic disorder (with or 
without agoraphobia) on health care delivery and costs 
in Germany. This information is pivotal to answer differ-
ent questions, like “In which sectors are resource mainly 
utilized?”, “Which sectors need to be addressed by politi-
cal and medical interventions?” and “Has an intervention 
been successful in addressing these sectors?”.
In this study, we will present this pivotal information by 
performing an excess cost analysis of patients with panic 
disorder (with or without agoraphobia) in comparison 
to a representative sample of the German adult popula-
tion. By doing this, we will inform decision-makers on 
the allocation of health care resources, give them infor-
mation to govern this allocation, support researchers in 
the development of future interventions and enable the 
interpretation of the impact of these interventions on the 
delivery of health care services.
Methods
Study population
Two samples are needed to estimate excess costs. The 
first sample consists of patients who suffer from the dis-
order of interest. The second sample is a population not 
affected by the disorder. In any other characteristic, the 
samples must be comparable. For this reason, we bal-
anced the data of patients diagnosed with PD or PDA and 
data of individuals without anxiety disorders.
Patient data were collected in a cluster-randomized 
controlled trial including patients with panic disor-
der (PD) or panic disorder and agoraphobia (PDA) [12] 
(Current Controlled Trials: ISCRTN64669297). Patients 
had to be at least 18  years, diagnosed with PD (ICD-
10; F41.0) or PDA (ICD-10; F40.01) by a GP-led clinical 
interview, scored at least 8 points on the Overall Anxi-
ety Severity and Impairment Scale (OASIS) [13], and had 
a minimum of two positive answers on the panic mod-
ule of the ‘Patient Health Questionnaire’ (PHQ) [14, 15]. 
Patients were excluded if they had one of the following 
conditions: suicidal tendencies, psychotic or substance-
related disorders, severe physical illness, pregnancy, or if 
they were currently under psychotherapeutic treatment. 
In order to estimate excess costs, we used data from the 
baseline assessment, which included information about 
resource utilisation in the last 6 months before the assess-
ment, sociodemographic characteristics and information 
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on comorbidity. 419 patients were included in the study, 
315 (75%) were diagnosed with PDA and 104 (25%) with 
PD. To handle missing values (44.6% of all patients had at 
least one missing value), we applied Multiple Imputation 
by Chained Equations [16]. In total 40 datasets (m = 40) 
[17] were generated by predicted mean matching [18] 
using sociodemographic characteristics, comorbidities, 
disease-specific measures, and health care utilisation as 
covariates in the imputation models.
The dataset used for comparison came from a tel-
ephone survey [19]. The sample is representative of the 
total German-speaking population aged 18  years and 
older. The interview included questions regarding health 
care utilisation in the last 6 months, the disease history 
(see Table  2), the PHQ-4 [20, 21] as a screening tool 
for anxiety disorders or depression, the ISR-S [21, 22] 
as a screening tool for somatoform disorders as well as 
sociodemographic questions. In total, 5005 individu-
als completed the telephone interview. A description of 
the dataset can be found elsewhere [19]. As individuals 
in this dataset should serve as an anxiety free control 
group in our analysis, we excluded individuals with anxi-
ety disorders (n = 265) or with a score of at least 3 on the 
PHQ-4 anxiety module [21] (n = 1448). Furthermore, 78 
individuals with missing values were removed from the 
dataset, as it was not possible to impute both datasets. 
Overall, 3214 individuals remained in the dataset as “anx-
iety free group (AF)” for further analysis.
Health care utilisation and costs
Both studies were conducted by researchers from the 
same academic department by using approaches to data 
collection standardized in the department. The descrip-
tion of the single services as well as the units of measure-
ment (contacts, days, hours) were comparable in both 
studies. In both datasets, information on health care 
resource use in three different health care sectors was 
collected. In the outpatient sector, visits to a psychia-
trist/neurologist, psychologist/psychotherapist, general 
practitioner and other medical specialists were consid-
ered. In the inpatient sector, days in general, psychiatric 
and rehabilitation hospitals were assessed. In the home 
care sector, received hours of professional and informal 
caregiving (unpaid support and care provided by fam-
ily members and friends) were measured. Additionally, 
disease-related days away from work (absenteeism) were 
recorded.
We applied the societal perspective [23]. Direct health 
care costs, i.e. costs directly related to treatments of dis-
eases, were determined by valuing resource use data 
with German unit costs [24]. Indirect costs, i.e. produc-
tivity losses due to disease-related absence from work, 
were determined applying the human capital approach 
[25], valuing sick leave days with an average daily wage 
rate (including full- and part-time work, corrected for 
employees’ share of social contributions) [26]. All applied 
unit costs are reported in Table 1. Informal care has been 
monetarily valued by the replacement cost approach. The 
reference year of the cost calculation was 2012. If unit 
costs were not available for the base year, values were 
inflated to the year 2012 using the German consumer 
price index [27]. To avoid influence of outliners with high 
costs on the results we excluded individuals who had 
total healthcare costs above the 99th percentile (33 indi-
viduals in the AF group, 8 individuals in the PDA and 2 
individuals in the PD group).
Statistical analysis
In order to estimate excess costs of patients with PD and 
PDA in comparison to AF individuals, we applied a two-
stage approach, comprising the pre-processing and the 
estimation stage. The main analyses of these study were 
performed based on the imputed dataset. However, to 
assess the influence of the imputation method (MICE) 
on the results we re-ran sensitivity analyses based on the 
original dataset, which is the dataset without imputation. 
Additionally, we performed sensitivity analyses based on 
a sample including the cost outliers to assess the influ-
ence of the approach in our main analysis. All analyses 
were conducted in Stata 14 (StataCorp, Texas, USA).
The pre-processing stage was necessary because the 
three groups differed in terms of their covariates and 
were therefore not directly comparable. Hence, we 
reweighted the AF group on the PD and PDA group 
separately, applying the reweighting method of Entropy 
Table 1 Unit costs for different resource uses in 2012 Euros
Sources: direct costs: [24, 27]; indirect costs: 30.7€/h [26] assuming 8 h/day
Cost category Unit Price per unit (€)
Direct costs
 Outpatient sector
  Psychiatrist/neurologist Per visit 45.60
  Psychologist/psychotherapist Per visit 79.61
  General practitioner Per visit 20.45
  Other medical specialists Per visit 35.37
 Inpatient sector
  General hospital Per day 587.18
  Psychiatric hospital Per day 346.36
  Rehabilitation hospital Per day 124.24
 Home care sector
  Professional care Per hour 29.36
  Informal care Per hour 18.33
 Indirect costs
  Absenteeism Per day 245.6
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Balancing [28]. In Entropy Balancing covariates of a tar-
get group will be made comparable to those of a compari-
son group in reference to predefined moments. In case of 
our study, all available covariates (Table 2) were included 
and the predefined moments were the mean and the vari-
ance of the target group. The process is successful if the 
value of the adjusted moments of the covariates in the 
target group are similar to the corresponding moments 
of the comparison group, which means that the adjusted 
value of all included covariates is in a predefined area of 
tolerable deviation. In case of our study this tolerance 
level was set to 0.005, a rigorous level of tolerance (the 
default level set in STATA is 0.015). Entropy balancing 
works in such a way that every observation in the target 
group receives a balancing weight. This balancing weight 
represents the number of times the specific observation 
is considered in the process of adjusting the included 
covariates in terms of the predefined moments. The algo-
rithm varies the balancing weights until the moments 
of all included covariates of the target group are com-
parable to the moments of the comparison group [28]. 
A reweighted dataset is similar to a randomized trial, 
where both groups are expected to have no systematic 
difference in observed baseline characteristics. We chose 
this approach as it does not exclude members of the 
target group, reaches a higher degree of balance in the 
Table 2 Pre- and post-balanced covariates
AF anxiety free, PD panic disorder, PDA panic disorder with agoraphobia
a AF were balanced on covariate structure of the PD sample
b AF were balanced on covariate structure of the PDA sample
Covariates Pre-balancing Post-balancing
AF PD PDA AFa PD AFb PDA
(n = 3181) (n = 102) (n = 307) (n = 3181) (n = 102) (n = 3181) (n = 307)
Age (mean) 56.239 46.069 46.055 45.941 46.069 46.015 46.055
Gender (female %) 0.489 0.686 0.765 0.684 0.686 0.765 0.765
Person in partnership (%) 0.455 0.520 0.495 0.518 0.520 0.495 0.495
Average persons in household 2.012 2.451 2.454 2.444 2.451 2.451 2.454
Educational level (%)
 None 0.007 0.039 0.036 0.050 0.039 0.036 0.036
 Low 0.273 0.245 0.287 0.245 0.245 0.287 0.287
 Median 0.307 0.343 0.420 0.343 0.343 0.420 0.420
 High 0.413 0.363 0.257 0.362 0.363 0.257 0.257
 Employment rate (%) 0.458 0.588 0.616 0.586 0.588 0.615 0.616
Physical comorbidities (%)
 Lung disease 0.141 0.167 0.137 0.167 0.167 0.137 0.137
 Joint disease 0.295 0.069 0.143 0.069 0.069 0.143 0.143
 Metabolic disease 0.239 0.265 0.306 0.265 0.265 0.306 0.306
 Diabetes 0.107 0.029 0.101 0.029 0.029 0.101 0.101
 Chronic pain 0.238 0.039 0.046 0.039 0.039 0.046 0.046
 Gastrointestinal dis. 0.162 0.206 0.238 0.206 0.206 0.238 0.238
 Cancer 0.094 0.020 0.033 0.020 0.020 0.033 0.033
 Cardiovascular dis. 0.328 0.275 0.410 0.274 0.275 0.410 0.410
 Skin disease 0.124 0.049 0.078 0.049 0.049 0.078 0.078
 Osteoporosis 0.066 0.049 0.016 0.049 0.049 0.016 0.016
Mental comorbidities (%)
 Posttraumatic stress disorder 0.019 0.010 0.013 0.010 0.010 0.013 0.013
 Somatoform disorder 0.032 0.088 0.094 0.088 0.088 0.094 0.094
 Eating disorder 0.014 0.000 0.003 0.000 0.000 0.003 0.003
 ADHS 0.004 0.000 0.000 0.000 0.000 0.000 0.000
 Substance abuse 0.016 0.010 0.029 0.010 0.010 0.029 0.029
 Psychoses 0.005 0.000 0.003 0.000 0.000 0.003 0.003
 Depression 0.039 0.137 0.251 0.137 0.137 0.251 0.251
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covariates than other approaches, and does not require 
manual adjustments by the scientist, which is a source of 
computational delay and human error. Entropy Balancing 
was performed for each of the imputed dataset (m = 40) 
separately. To perform the method we used a user writ-
ten Stata program (Ebalance) by Hainmueller et al. [29].
In the estimation stage, we estimated mean cost dif-
ferences (excess costs) between the groups for each cost 
category (Table 3). As costs cannot reach negative values, 
are often skewed, and sometimes have a large number 
of ‘zero’ values [30], the choice of an appropriate statis-
tical model is an important step in modelling costs. For 
cost categories with a small number of ‘zeros’, costs were 
modelled using a generalized linear model (GLM) with 
gamma family and log-link function [31]. For cost cat-
egories with a large number of ‘zeros’, a two-part (TP) 
model approach was applied [32]. In the first part of the 
TP-model we used a logit model in order to estimate 
the probability of positive costs, in the second part we 
used a GLM with gamma family and log-link function 
to estimate costs in patients with positive costs [32]. The 
TP-model was estimated using the user-written Stata 
command twopm by Belotti et al. [32]. Mean differences 
in costs were obtained by calculating margins [32], which 
means we predicted the cost difference between the 
groups based on the results of the previously run model 
under consideration of the specific cost distribution. 
These results are referred to as excess costs in the further 
course of this article. As the twopm and margin com-
mand is not supported under Stata’s “mi estimate option”, 
we estimated 40 separate regression models (TPMs and 
GLMs) and combined the results using Rubin’s pool-
ing rules for multiple imputed datasets [33]. All regres-
sions were conducted as weighted regressions using the 
balancing weights from the pre-processing stage [28]. 
The only independent variable in all regressions was the 
group variable [PD or PDA (yes/no)]. We did not include 
further covariates into regression analyses as all observed 
covariates were already included in the Entropy balanc-
ing and would not have any further effect on averages of 
cost estimates [34].
Results
The pre- and post-balancing results of the demographic 
and clinical characteristics for individuals from the AF 
population and patients with PDor PDA are shown 
in Table  2. By using entropy balancing we reached a 
high degree of concordance between the groups, in all 
included covariates.
The results of the cost-analysis of the AF group in com-
parison to the PD group are shown in Tables 3 and 4. As a 
main result, we found average (SD) 6-month total costs of 
Table 3 Average per capita 6-month costs of AF, PD and PDA for different cost categories in 2012 Euros
AF costs are post balanced estimates
AF anxiety free, PD panic disorder, PDA panic disorder with agoraphobia, SD standard derivation
a AF were balanced on covariate structure of the PD sample
b AF were balanced on covariate structure of the PDA sample
AFa PD AFb PDA
(n = 3181) (n = 102) (n = 3181) (n = 307)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Direct costs
 Outpatient sector
  Psychiatrist/neurologist 5 (2) 24 (14) 8 (3) 23 (5)
  Psychologist/psychotherapist 17 (4) 106 (35) 21 (5) 139 (20)
  General practitioner 34 (1) 164 (13) 40 (2) 169 (9)
  Other medical specialists 120 (8) 140 (19) 138 (12) 120 (11)
 Inpatient sector
  General hospital 251 (46) 771 (197) 282 (86) 556 (106)
  Psychiatric hospital 4 (2) 28 (66) 7 (4) 338 (141)
  Rehabilitation hospital 28 (12) 137 (135) 35 (15) 221 (91)
 Home care sector
  Professional care 12 (4) 1 (2) 7 (3) 2 (2)
  Informal care 71 (25) 438 (170) 95 (31) 673 (149)
Total direct cost 542 (61) 1809 (354) 631 (103) 2242 (298)
Total indirect cost (Absenteeism) 427 (73) 2380 (531) 498 (99) 2830 (355)
Total cost 969 (110) 4189 (658) 1129 (184) 5072 (473)
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969€ (110€) in the AF group and 4189€ (658€) in the PD 
group, resulting in significant 6-month total excess costs 
of 3220€ (95% CI 1917€–4522€) for patients with PD 
in comparison to AF individuals. About 1953€ (95% CI 
909–2996€) of the 6-month total excess costs were indi-
rect costs due to absenteeism. This corresponds to 61% 
of the total excess costs. The largest share of the direct 
excess costs of 1267€ (95% CI 565€–1969€) was incurred 
by statistically significant general hospital excess costs of 
520€ (95% CI 124€–916€) and excess costs due to infor-
mal care of 367€ (95% CI 31€–703€). In the outpatient 
sector we found significant excess costs of 130€ (95% CI 
104€–155€) caused by visits to general practitioner and 
excess costs of 89€ (95% CI 19€–159€) for psychologist 
or psychotherapist visits. We found no statistically sig-
nificant excess costs for treatments by other medical spe-
cialists, psychiatrists/neurologists, and for treatments in 
psychiatric or rehabilitation hospitals.
As shown in Tables  3 and 4, patients with PDA had 
average (SD) 6-month total costs of 5072€ (473€) com-
pared to 1129€ (184€) in AF individuals, resulting in sta-
tistically significant total excess costs of 3943€ (95% CI 
2950€–4936€). The share of indirect cost (2331€ (95% CI 
1617€–3045€)) was 59%. The largest share of the direct 
excess costs (1612€ (95% CI 994€–2229€)) in the PDA 
group were excess costs of 579€ (95% CI 281€–876€) for 
informal care. In the inpatient sector, statistically signifi-
cant excess costs incurred for psychiatric (331€ (95% CI 
53€–610€)), general (275€ (95% CI 14€–535€)) and reha-
bilitation hospital stays (187€ (95% CI 6€–368€)). In the 
outpatient sector, excess costs incurred for treatments by 
general practitioners (130€ (95% CI 112€–148€) and psy-
chologists or psychotherapists (119€ (95% CI 78€–159€)). 
Low but statistically significant excess costs were found 
for treatments by psychologists or psychotherapists with 
15€ (95% CI 2€–27€). Excess costs for treatment by other 
medical specialists were not statistically significant.
The sensitivity analyses on the imputation of missing 
values led to results comparable to the results of the 
main analyses (Appendix Table  5). The amount of the 
excess costs decreased in several cost categories and 
the CI of the costs for inpatient rehabilitation services 
crossed the 0€ threshold, leading to an insignificant 
group difference. The sensitivity analyses considering 
the cost outliers showed no noticeable deviating results 
in the comparison of AF and PD. However, in the 
comparison of AF and PDA, we observed that in the 
inpatient sector the cost differences in general and psy-
chiatric hospital services were not statistically signifi-
cant anymore. The small sample size of the PDA group 
and the high cost in the inpatient sector could be an 
explanation for this.
Table 4 6-month per capita excess cost of PD and PDA for different cost categories in 2012 Euros
AF costs are post balanced estimates
AF anxiety free, PD panic disorder, PDA panic disorder with agoraphobia
a AF were balanced on covariate structure of the PD sample
b AF were balanced on covariate structure of the PDA sample
AFa group vs. PD group AFb group vs. PDA group
Excess 95% CI p-value Excess 95% CI p-value
Direct costs
 Outpatient sector
  Psychiatrist/neurologist 19 (− 9 to 47) 0.191 15 (2 to 27) 0.020
  Psychologist/psychotherapist 89 (19 to 159) 0.012 119 (78 to 159) < 0.000
  General practitioner 130 (104 to 155) < 0.000 130 (112 to 148) < 0.000
  Other medical specialists 21 (− 20 to 61) 0.313 − 18 (− 51 to 14) 0.261
 Inpatient sector
  General hospital 520 (124 to 916) 0.010 275 (14 to 535) 0.039
  Psychiatric hospital 24 (− 107 to 155) 0.718 331 (53 to 610) 0.020
  Rehabilitation hospital 109 (− 156 to 374) 0.422 187 (6 to 368) 0.043
 Home care sector
  Professional care − 11 n. a n. a − 5 n. a n. a
  Informal care 367 (31 to 703) 0.032 579 (281 to 876) < 0.000
Total direct  costa 1267 (565 to 1969) < 0.000 1612 (994 to 2229) < 0.000
Total indirect cost (Absenteeism) 1953 (909 to 2996) < 0.000 2331 (1617 to 3045) < 0.000
Total cost 3220 (1917 to 4522) < 0.000 3943 (2950 to 4936) < 0.000
Page 7 of 11Brettschneider et al. Cost Eff Resour Alloc            (2019) 17:9 
Discussion
Our analysis showed that PD and PDA raised health 
care costs (direct costs) and productivity losses (indi-
rect costs) substantially. Around 60% of total costs were 
caused by productivity losses due to absenteeism. In 
the first instance, productivity losses are a loss to the 
economy and society and not necessarily influenced by 
resource allocation. However, scrutinizing the composi-
tion of excess cost for health care resources, our results 
indicate that there could be an interconnection between 
resource allocation and absenteeism. The utilization of 
general hospital services by PD patients is the resource 
category associated with the largest difference in costs. 
For PDA patients only the difference in informal care 
was larger. It is obvious that a higher utilization of hos-
pital services goes along with a higher degree of absen-
teeism. This is an important aim for policy and medical 
interventions. Measures structured to shift the emphasis 
of treatment from the inpatient to the outpatient sector 
could not only result in lower health care costs but also 
in smaller losses of economic productivity. However, in 
this context it is indicated to differentiate between PD 
and PDA. While PDA showed an increase of inpatient 
service utilization in all subtypes of hospitals—and the 
largest increase for utilization of psychiatric hospitals—, 
PD showed a pronounced increase for general hospital 
services exclusively.
This pronounced excess utilization of general hos-
pital services by PD patients can be interpreted as a 
direct result of a panic attack, which manifests with 
distinct somatic symptoms like chest pain, dizziness 
and breathing difficulties [1]. These symptoms can lead 
to the assumption of a severe physical and maybe even 
life-threatening disease. In this situation, people will be 
admitted to a hospital, maybe as emergency, and will first 
underwent a thorough evaluation in the inpatient setting. 
This process utilized resources in an unproductive way. 
There are different explanations for this. For example, (a) 
the patient was not diagnosed with a panic disorder, (b) 
the patient is not informed about the nature of his dis-
order, (c) the clinical staff is not qualified enough to dif-
ferentiate between a heart attack and a panic attack with 
comparable symptoms or (d) clinical pathways demand 
that a patient showing these symptoms has to be hos-
pitalized for a rigorous examination. Although some of 
these problems have been addressed before [35], the rea-
sons for the hospitalization of PD patients in a general 
hospital has to be evaluated more thoroughly in further 
research.
In case of PDA, the situation is different. General hos-
pital and psychiatric hospital services are both utilized 
to a high degree. This is not necessarily a miss-allocation 
as patients with PDA receive professional services in 
accordance with their disorder. Yet, the question arises 
whether these services must be delivered in an inpatient 
setting. It could be worthwhile to develop outpatient-
based intervention for PDA to reduce the length of hos-
pital stays [12, 36].
In the outpatient sector, the utilization of mental health 
services is more pronounce for PDA patients in compar-
ison to PD patients. This in combination with the utili-
zation of inpatient mental health care services could be 
regarded as indicator for a greater health burden of PDA 
and hence an increased need for services or a greater 
awareness of need for support. However, the excess costs 
for general practitioner (GP) services were comparable 
for PD and PDA. This and the relatively high costs for GP 
services (Table  3) could be an indicator for the impor-
tant part the GP has in the care for PD and PDA patients. 
This important role of the GP poses a risk and a chance. 
The risk is that the GP might be not qualified enough to 
provide or has no access to PD(A)-targeted services. The 
chance is that the GP as access point for patients into 
the health care system could be a valuable stakeholder 
in the care process by providing identification, education 
and early treatment [12]. Consequently, interventions to 
empower the GP to identify PD and PDA, to educate the 
patient and to offer first-line support could be a valuable 
addition to the services offered by mental health special-
ists, especially in the German setting, where waiting peri-
ods for psychotherapy are quite long [37].
The elevated costs for informal care, can be consid-
ered as manifestation of a high degree of need for sup-
port. This transfers a part of health care provision into 
the informal and hence unpaid sector. This relieves the 
health care budget and promotes the flexibility of service 
delivery, as family members, friends and neighbours can 
offer support in a variety of small tasks on short notice. 
However, there is evidence that the provision of informal 
care, can lead to worse health and a loss of income on the 
part of the provider of informal care [38, 39]. This in turn 
affects the health care budget and societal productivity.
Strengths of our study include the used data sources 
and the analytical approach. In our study we com-
bined data from a representative population survey [19] 
with baseline data from a high quality clinical trial with 
patients diagnosed with panic disorder (with and without 
agoraphobia) [12]. The combination of these two datasets 
enabled a valid comparison of panic disorder patients 
with the general population. In order to reach compa-
rability of the datasets, it is essential to apply elaborated 
matching or balancing methods. For this reason we 
applied an innovative reweighting method, Entropy Bal-
ancing [28]. In comparison to other matching methods 
(e.g. propensity score matching), Entropy Balancing is 
favourable and advantageous [28]. In validation analyses, 
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Entropy Balancing showed a higher degree of balance in 
covariates in comparison to other common processing 
adjustments (matching methods), e.g. propensity score or 
genetic matching [28].
Some limitations should be considered when inter-
preting our results. As two independent samples 
where used in this analysis, some data adjustments 
had to be performed. The assessment of visits to other 
medical specialist and comorbidities was differently 
conducted in the datasets. Therefore, data had to be 
aggregated. Furthermore, the mode of the assessment 
of comorbidities was different. In the clinical trial gen-
eral practitioners coded diagnosis, while in the general 
population sample patients reported their diagnosed 
comorbidities.
In the main analysis of this study, AF individuals from 
the general population dataset were compared to individ-
uals with PD and PDA. To determine the population of 
AF individuals from the general population dataset, indi-
viduals with a diagnosed anxiety disorder or with a score 
of ≥ 3 in the anxiety module of the PHQ-4 [20] were 
excluded. All other mental comorbidity variables of this 
AF group were used in the Entropy Balancing in order 
to create a comparable comparison group to the PD and 
PDA group in term of mental comorbidities. As anxiety 
disorders are often diagnosed with other severe mental 
disorders [40–44], it is possible that the balanced individ-
uals in the AF group had relative mild mental comorbidi-
ties and therefore low health care costs in the psychiatric 
cost categories.
Finally, we want to declare that despite the efforts of 
mitigating the effects of missing values and differences in 
sample characteristics by using MICE and entropy bal-
ancing, we cannot warrant that the results of our analyses 
are not influenced by any kind of bias. Entropy balancing 
led to a high degree of comparability between the groups 
in measured variables and missing values were imputed 
by an approach considering uncertainty. However, as 
both approaches are based exclusively on measured 
variables, they have no direct influence on unobserved 
heterogeneity.
Conclusion
Panic disorder is associated with high excess costs and 
constitutes a major economic challenge to health care 
system and society. Resources are mainly utilized in the 
inpatient sector. The development of measures to iden-
tify, educate and treat patients in the outpatient sector 
could optimize resource allocation. This approach could 
also lead to a reduction of absenteeism. Further research 
is needed. Additionally, panic disorder not only affects 
the patient but also his or her personal/familial net-
work. This could lead to further health and occupational 
consequences.
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Table 5 6-month per capita excess cost of PD and PDA for different cost categories in 2012 Euros (complete case analysis)
AF costs are post balanced estimates
AF anxiety free, PD panic disorder, PDA panic disorder with agoraphobia
a AF were balanced on covariate structure of the PD sample
b AF were balanced on covariate structure of the PDA sample
AFa group vs. PD group AFb group vs. PDA group
Excess 95% CI p-value Excess 95% CI p-value
Direct costs
 Outpatient sector
  Psychiatrist/neurologist 19 (− 10 to 48) 0.198 15 (3 to 28) 0.019
  Psychologist/psychotherapist 89 (19 to 159) 0.013 119 (78 to 159) < 0.000
  General practitioner 129 (104 to 154) < 0.000 128 (111 to 146) < 0.000
  Other medical specialists 20 (− 21 to 62) 0.331 − 19 (− 51 to 13) 0.243
 Inpatient sector
  General hospital 539 (134 to 943) 0.009 261 (4 to 518) 0.046
  Psychiatric hospital 0.30 (− 9 to 9) 0.948 239 (32 to 447) 0.024
  Rehabilitation hospital 50 (− 41 to 141) 0.422 192 (− 2 to 385) 0.052
 Home care sector
  Professional care − 11 n. a n. a − 5 n. a n. a
  Informal care 284 (58 to 510) 0.014 563 (274 to 852) < 0.000
Total direct  costa 782 (150 to 1415) 0.015 840 (337 to 1343) 0.001
Total indirect cost (Absenteeism) 2023 (936 to 3110) < 0.000 2173 (1482 to 2863) < 0.000
Total cost 3044 (1368 to 4720) < 0.000 2933 (1909 to 3957) < 0.000
Table 6 6-month per  capita excess cost of  PD and  PDA for  different cost categories in  2012 Euros (Sensitivity analysis: 
outlier included)
AF costs are post balanced estimates
AF  anxiety free, PD panic disorder, PDA panic disorder with agoraphobia
a AF were balanced on covariate structure of the PD sample
b AF were balanced on covariate structure of the PDA sample
AFa group vs. PD group AFb group vs. PDA group
Excess 95% CI p-value Excess 95% CI p-value
Direct costs
 Outpatient sector
  Psychiatrist/neurologist 18 (− 9 to 46) 0.190 13 (0 to 25) 0.044
  Psychologist/psychotherapist 94 (25 to 164) 0.008 116 (74 to 157) < 0.000
  General practitioner 128 (103 to 153) <0.000 137 (117 to 157) < 0.000
  Other medical specialists 20 (− 20 to 59) 0.330 − 14 (− 45 to 18) 0.387
 Inpatient sector
  General hospital 619 (134 to 1104) 0.012 306 (− 190 to 802) 0.227
  Psychiatric hospital 8 (− 123 to 139) 0.904 298 (− 58 to 654) 0.101
  Rehabilitation hospital 131 (− 137 to 400) 0.338 191 (11 to 372) 0.038
 Home care sector
  Professional care − 11 n. a n. a − 5 n. a n. a
  Informal care 378 (29 to 727) 0.034 686 (340 to 1031) < 0.000
Total direct  costa 1386 (583 to 2189) 0.001 1733 (819 to 2647) < 0.000
Total indirect cost (Absenteeism) 2402 (1111 to 3694) < 0.000 2598 (1763 to 3433) < 0.000
Total cost 3788 (2076 to 5500) < 0.000 4331 (2905 to 5757) < 0.000
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